← back to search

Peter Rhein

Charité - Universitätsmedizin Berlin · DE
Area of research
Public Health, Environmental and Occupational Health · Hematology
Research interest
Research focused on Lymphoblastic Leukemia and Flow cytometry, with related work in Minimal residual disease, Circulating tumor cell, Myeloid leukemia. Notable publications include 'ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia', 'Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia', and 'High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol'.
h-index
citations
241
works
6
NIH funding
primary concept
email

Recent publications

Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints
Nature Immunology 2026cited by 6position: middledoi
(090) Hydrogen Sulfide Therapy Stimulates Cellular Antioxidant Defense and Reverses Erectile Dysfunction in Western Diet-fed Mice
The Journal of Sexual Medicine 2023cited by 1position: middledoi
Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers
Cancers 2022cited by 10position: middledoi
<i>NOTCH1</i> mutation, <i>TP53</i> alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia
Haematologica 2017cited by 8position: middledoi
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia
Haematologica 2015cited by 75position: middledoi
ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia
Leukemia 2013cited by 95position: middledoi
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol
Haematologica 2013cited by 47position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Leonid Karawajew · Charité - Universitätsmedizin Berlin4 papers (2013–2017)Cornelia Eckert · Deutschen Konsortium für Translationale Krebsforschung3 papers (2013–2017)Richard Ratei · Charité - Universitätsmedizin Berlin3 papers (2013–2017)Andreas E. Kulozik · German Cancer Research Center2 papers (2013–2017)Obul Reddy Bandapalli · German Cancer Research Center2 papers (2013–2017)Martina U. Muckenthaler · University Medical Centre Mannheim2 papers (2013–2017)Wolfgang Ludwig · German Medical Association2 papers (2015–2017)Arend von Stackelberg · Charité - Universitätsmedizin Berlin2 papers (2015–2017)Stephanie Staudte · German Cancer Research Center1 papers (2022–2022)M. Stanulla · Medizinische Hochschule Hannover1 papers (2013–2013)Martin Stanulla · Medizinische Hochschule Hannover1 papers (2013–2013)Sandra Liebs · Charité - Universitätsmedizin Berlin1 papers (2022–2022)Martin Schrappe · University Hospital and Clinics1 papers (2013–2013) · 1 papers (2015–2015)Jens‐Uwe Blohmer · Berlin Institute of Health at Charité - Universitätsmedizin Berlin1 papers (2022–2022)Paul Jank · University Hospital Frankfurt1 papers (2022–2022)Philipp Jurmeister · German Cancer Research Center1 papers (2022–2022)Rita Mitlöhner · Charité - Universitätsmedizin Berlin1 papers (2013–2013)Ondřej Hrušák · Charles University1 papers (2015–2015) · 1 papers (2013–2013)